Stock Quality:
Last 7 days
0.6%
Last 30 days
-1.7%
Last 90 days
2.3%
Trailing 12 Months
16.7%
ALPN RSI Chart
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
Historical Charts for Stock Metrics
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 56.5M | 0 | 0 | 0 |
| 2023 | 25.8M | 29.1M | 30.8M | 58.9M |
| 2022 | 33.9M | 32.0M | 31.8M | 30.1M |
| 2021 | 11.4M | 18.0M | 24.6M | 23.4M |
| 2020 | 2.8M | 3.0M | 4.6M | 9.3M |
| 2019 | 0 | 1.1M | 1.4M | 1.7M |
| 2018 | 1.5M | 1.1M | 910.2K | 705.0K |
| 2017 | 2.6M | 2.3M | 2.0M | 1.7M |
| 2016 | 0 | 0 | 1.7M | 3.0M |
| 2015 | 0 | 0 | 0 | 492.0K |
| CEO | Dr. Mitchell H. Gold M.D. |
|---|---|
| WEBSITE | alpineimmunesciences.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 126 |